Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antiviral target compound profile for pandemic preparedness.
Demarest JF, Draghia-Akli R, Cihlar T, Bradley K, Young JAT, Chandra R, Vaidyanathan S, Chu-Moyer M, Lynch CL, Campbell A, Saikatendu KS, Bilello JP, Murata Y, van Loock M, Hurt AC, Tellinghuisen T, Ruggiero L, Mackman R, Hill NM, Pottage JC Jr; INTREPID Alliance. Demarest JF, et al. Among authors: draghia akli r. Nat Rev Drug Discov. 2024 Dec 2. doi: 10.1038/s41573-024-01102-3. Online ahead of print. Nat Rev Drug Discov. 2024. PMID: 39622985 No abstract available.
Preparing better: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) therapeutics trials lessons learned: A call to the future.
Adam SJ, Buchman TG, Currier JS, Draghia-Akli R, Fessel JP, Higgs ES, Hughes EA, LaVange L, Menetski JP, Read SW, Rosenberg Y, Tressler R; ACTIV Therapeutics-Clinical Working Group. Adam SJ, et al. Among authors: draghia akli r. J Clin Transl Sci. 2024 Oct 15;8(1):e150. doi: 10.1017/cts.2024.178. eCollection 2024. J Clin Transl Sci. 2024. PMID: 39478782 Free PMC article. Review.
Overview of ACTIV trial-specific lessons learned.
Draghia-Akli R, Read SW, Hughes EA. Draghia-Akli R, et al. J Clin Transl Sci. 2024 Oct 15;8(1):e149. doi: 10.1017/cts.2023.698. eCollection 2024. J Clin Transl Sci. 2024. PMID: 39478781 Free PMC article. Review.
The case for a global therapeutics development coalition: Building a therapeutics pipeline for pandemic and endemic diseases.
Machingaidze S, Pérez Casas C, Mburu S, Draghia-Akli R, Mowbray C, Rosen J, Burrone E, Nemer M, Dzau V. Machingaidze S, et al. Among authors: draghia akli r. PLOS Glob Public Health. 2024 Aug 30;4(8):e0003654. doi: 10.1371/journal.pgph.0003654. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39213286 Free PMC article. No abstract available.
Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study.
Jensen TO, Murray TA, Grandits GA, Jain MK, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens R, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Jensen TO, et al. Lancet Microbe. 2024 Jun;5(6):e559-e569. doi: 10.1016/S2666-5247(24)00015-6. Epub 2024 May 27. Lancet Microbe. 2024. PMID: 38815595 Free article.
Viral and Host Factors Are Associated With Mortality in Hospitalized Patients With COVID-19.
Aggarwal NR, Nordwall J, Braun DL, Chung L, Coslet J, Der T, Eriobu N, Ginde AA, Hayanga AJ, Highbarger H, Holodniy M, Horcajada JP, Jain MK, Kim K, Laverdure S, Lundgren J, Natarajan V, Nguyen HH, Pett SL, Phillips A, Poulakou G, Price DA, Robinson P, Rogers AJ, Sandkovsky U, Shaw-Saliba K, Sturek JM, Trautner BW, Waters M, Reilly C; ACTIV-3/TICO Study Group. Aggarwal NR, et al. Clin Infect Dis. 2024 Jun 14;78(6):1490-1503. doi: 10.1093/cid/ciad780. Clin Infect Dis. 2024. PMID: 38376212 Clinical Trial.
Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19.
Jensen TO, Grandits GA, Jain MK, Murray TA, Grund B, Shaw-Saliba K, Matthay MA, Abassi M, Ardelt M, Baker JV, Chen P, Dewar RL, Goodman AL, Hatlen TJ, Highbarger HC, Holodniy M, Lallemand P, Laverdure S, Leshnower BG, Looney D, Moschopoulos CD, Mugerwa H, Murray DD, Mylonakis E, Nagy-Agren S, Rehman MT, Rupert A, Stevens RA, Turville S, Weintrob A, Wick K, Lundgren J, Ko ER; ACTIV-3/TICO Study Group. Jensen TO, et al. J Infect Dis. 2024 Mar 14;229(3):671-679. doi: 10.1093/infdis/jiad446. J Infect Dis. 2024. PMID: 37948759 Free PMC article. Clinical Trial.
The 100 Days Mission: how a new medical-countermeasures network can deliver equity and innovation.
Dzau V, Swaminathan S, Baker C, Bright RA, Castillo J, Chuan TC, Draghia-Akli R, Eardley-Patel R, Gao GF, Ishii K, Tebeje YK, Lambe T, Machingaidze S, Røttingen JA, Shaligram U, Simão M, Swarup R, Toussaint JF, Wairagkar NS. Dzau V, et al. Among authors: draghia akli r. Lancet. 2023 Oct 28;402(10412):1507-1510. doi: 10.1016/S0140-6736(23)01775-0. Epub 2023 Sep 6. Lancet. 2023. PMID: 37683681 No abstract available.
Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.
Brown SM, Barkauskas CE, Grund B, Sharma S, Phillips AN, Leither L, Peltan ID, Lanspa M, Gilstrap DL, Mourad A, Lane K, Beitler JR, Serra AL, Garcia I, Almasri E, Fayed M, Hubel K, Harris ES, Middleton EA, Barrios MAG, Mathews KS, Goel NN, Acquah S, Mosier J, Hypes C, Salvagio Campbell E, Khan A, Hough CL, Wilson JG, Levitt JE, Duggal A, Dugar S, Goodwin AJ, Terry C, Chen P, Torbati S, Iyer N, Sandkovsky US, Johnson NJ, Robinson BRH, Matthay MA, Aggarwal NR, Douglas IS, Casey JD, Hache-Marliere M, Georges Youssef J, Nkemdirim W, Leshnower B, Awan O, Pannu S, O'Mahony DS, Manian P, Awori Hayanga JW, Wortmann GW, Tomazini BM, Miller RF, Jensen JU, Murray DD, Bickell NA, Zatakia J, Burris S, Higgs ES, Natarajan V, Dewar RL, Schechner A, Kang N, Arenas-Pinto A, Hudson F, Ginde AA, Self WH, Rogers AJ, Oldmixon CF, Morin H, Sanchez A, Weintrob AC, Cavalcanti AB, Davis-Karim A, Engen N, Denning E, Taylor Thompson B, Gelijns AC, Kan V, Davey VJ, Lundgren JD, Babiker AG, Neaton JD, Lane HC; ACTIV-3b/Therapeutics for Severely Ill Inpatients with COVID-19 (TESICO) Study Group. Brown SM, et al. Lancet Respir Med. 2023 Sep;11(9):791-803. doi: 10.1016/S2213-2600(23)00147-9. Epub 2023 Jun 19. Lancet Respir Med. 2023. PMID: 37348524 Free PMC article. Clinical Trial.
103 results